Compare BRCB & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRCB | IMMX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | 2800 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.8M | 306.2M |
| IPO Year | N/A | 2021 |
| Metric | BRCB | IMMX |
|---|---|---|
| Price | $12.26 | $8.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $26.83 | $19.00 |
| AVG Volume (30 Days) | 615.2K | ★ 725.5K |
| Earning Date | 03-03-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.77 | N/A |
| Revenue Next Year | $24.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.51 | $1.34 |
| 52 Week High | $30.40 | $11.61 |
| Indicator | BRCB | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 31.47 | 47.72 |
| Support Level | $11.51 | $2.20 |
| Resistance Level | $17.60 | $8.97 |
| Average True Range (ATR) | 1.10 | 0.95 |
| MACD | -0.39 | -0.29 |
| Stochastic Oscillator | 5.46 | 14.68 |
Black Rock Coffee Bar Inc is an operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by its engaging baristas. The company offers wide variety of coffee from classic espresso-based drinks such as Lattes, Americanos, and Cappuccinos, as well as signature creations like the Caramel Blondie, Mexican Mocha, and Blackout. It offers a variety of savory and sweet items, including breakfast burritos, sausage cheddar sandwiches, banana bread, and glazed donut holes.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.